NIH Grants & Funding /
Activity Code: R61/R33
| FOA Number | Co-Funders | Title | Clinical Trial | Activity Code | Application Due Date |
|---|---|---|---|---|---|
| PAR-23-158 | National Institute on Drug Abuse (NIDA) | Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required) | Basic Experimental Studies with Humans are required. | R61/R33 | June 21, 2023 | October 09, 2023 | March 13, 2024 | June 20, 2024 | October 09, 2024 | March 13, 2025 | June 20, 2025 | October 09, 2025 | March 13, 2026 |
| RFA-DA-24-024 | National Institute on Drug Abuse (NIDA) | Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required) | Required | R61/R33 | ClosedNovember 02, 2023 |
| PAR-22-055 | National Institute of Neurological Disorders and Stroke (NINDS) | Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets | Not allowed | R61/R33 | ClosedMarch 15, 2022; March 14, 2023; and March 14, 2024 |
| PAR-21-122 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |
| PAR-21-123 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |
| PAR-21-124 | National Institute of Neurological Disorders and Stroke (NINDS) | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification | Not allowed | R61/R33 | ClosedOctober 19, 2021 to February 20, 2024 |